Five Arrows Principal Investments to acquire Sygnature Discovery from Phoenix Equity Partners.

Five Arrows Principal Investments, the European private equity arm of Rothschild, agreed to acquire Sygnature Discovery, an integrated drug discovery and non-clinical solutions provider, from Phoenix Equity Partners, a private equity firm. Financial terms were not disclosed. “Our partnership with the Phoenix team has been invaluable; they shared our ambitions for the Company and were instrumental in helping us with our acquisition strategy. We are delighted to welcome Five Arrows as a shareholder alongside the Sygnature team and are excited about what the future holds for our Company," Simon Hirst, Sygnature CEO.